Found 148 investors
Bill Stapleton
United States
Dr. Frederick Feit served as Board Member at Salus Telehealth. He also served as President and Board Member at Video Medicine. He is the Director of the Fellowship Training Program in Interventional Cardiology, and Associate Professor of Medicine at the NYU Langone School of Medicine, is recognized nationally and internationally for his scientific contributions and technical expertise. His pioneering research in collaboration with Dr. Rentrop, beginning in the Summer of 1981 was truly revolutionary in that he and his team injected thrombolytic agents (clot busting drugs) directly into totally obstructed coronary arteries of patients experiencing myocardial infarctions (heart attacks). These catheter-based, invasive, but non-surgical procedures were at the time considered to be too dangerous to perform during a myocardial infarction. Feit and his team not only proved that the procedure was safe, but that the clot-buster could restore blood flow and stop the progress of the heart attack. Subsequently, Dr. Feit has been Principal Investigator on numerous NIH-sponsored clinical trials involving patients with coronary artery disease those with diabetes mellitus and has served as Head of the Steering Committee of a Major International Trial.
Individual/Angel
BIND 4.0
Spain
BIND 4.0 is a public-private acceleration of the Basque Country. It focuses on Advanced Manufacturing, Smart Energy, Health Tech, and Food Tech early-stage startups, which includes big data, additive manufacturing, artificial vision, augmented and virtual reality, cybersecurity, IoT, artificial intelligence, robotics, and other 4IR technologies. The program will provide selected startups with the opportunity to create relationships with partner companies as customer-suppliers. There are 57 partner companies such as ABB, CAF, Bridgestone, Mercedes-Benz, Orona, Michelin, Repsol-Petronor, EDP, Iberdrola, Siemens Gamesa, Faes Farma, Ulma, Coca-Cola European Partners or Unilever, among others. Entering its 5th edition and global open call, BIND 4.0 has already accelerated a total of 108 Startups and developed over 175 Innovative Projects which have generated more than 4.5 Million Euros in turnover for participating over 100 so far. ADVANTAGES for Startups: - Up to €150,000 contract with a top industry firm (45k average paid contract) - At least one Industry Leading Company as a Client and Reference - +55 Top Industrial Companies looking for Dynamic Startups - Collaboration and Real Use application for Industry 4.0 Projects - Networking & Immersion into the Basque Industrial Ecosystem - No Equity nor Fees, due to Public-Private nature of the program - Investment Opportunities through BIND 4.0 Venture Club - Support Services offering Visibility, Mentoring, and Growth.
Accelerator
Incubator
BMW North America Collaboration Lab
Columbus, Ohio, United States
BMW North America Collaboration Lab provides entrepreneurs, start-ups, and small businesses in fintech and other fields.
Accelerator
Brian Harrold
United States
Ms. Ellie Wheeler serves as Partner at Greycroft Partners. She serves as Board Observer at Boulder Care, Elevate CBD. She serves as a Board Member at Elevate, Boost Insurance and Eden Health. She served as a Board Observer at Savoteur and HealthReveal and serves as an Advisor at Fisoc. She served as Board Observer at NuOrder. Her responsibilities include evaluating investment opportunities, sourcing new deals, and working with existing portfolio companies. Prior to joining Greycroft, she worked in a similar role during business school evaluating investment opportunities at Lowercase Capital with investor Chris Sacca. Before working with Lowercase, she worked at Cisco in Corporate Development doing acquisitions, investments, and strategy within the communications, collaboration, and video verticals. Her past experience also includes working briefly at the London-based venture capital firm DN Capital, focused on early-stage eCommerce companies. She began her career in growth capital private equity at Summit Partners in Boston. She graduated magna cum laude from Georgetown University with a BA in Psychology and holds an MBA from Harvard Business School.
Individual/Angel
Broadscale Group
United States
Founded in 2012, Broadscale Group is a venture capital investment firm based in New York, New York. The firm primarily focused on the energy transition, advanced transportation, and sustainable technologies. Broadscale operates a corporate Network of leading global energy and industrial firms, for which it sources strategic investments, partnerships and acquisitions and fosters peer-to-peer engagement and collaboration. The firm has selected over 130 venture-backed startups to engage with its corporate Network and these firms have raised more than $13 billion. It has also made ESG investments across energy and mobility industries.
Growth Capital
Business Alumni Network
Phoenix, Arizona, United States
A Premier Business Network and Collaboration Platform
Angel Group
Cambridge Future Tech
United Kingdom
Cambridge Future Tech is a venture builder that provides inventors, innovators and founders with the tools and collaboration required to succeed in building a deep tech company. The firm drives the commercialization of bleeding-edge innovation we work directly with researchers and inventors to commercialize their technologies. It is based in Cambridge, United Kingdom and was founded in 2020.
Strategic Acquirer
CATALYST startup accelerator
Bangalore, Karnataka, India
CATALYST startup accelerator program embodies collaboration and innovation.
Accelerator
Cedars-Sinai Accelerator
Los Angeles, California, United States
Cedars-Sinai Accelerator is a collaboration to help today’s technology innovators turn their ideas into breakthroughs.
Finance
Health Care
Information Technology
Accelerator
Center For Integration Of Medicine & Innovative Technology
United States
Center For Integration Of Medicine & Innovative Technology is a network of academic and medical institutions partnering with industry and government. A non-profit consortium of Boston's leading teaching hospitals and universities, CIMIT fosters interdisciplinary collaboration among world.
Strategic Acquirer
Charles Dunston
United States
Dr. Michael Ramsey is a Scientific Founder of 908 Devices and serves as its Board Member. He co-founded and served as Board Member at Genturi. He is the Goldby Distinguished Professor of Chemistry at the University of North Carolina - Chapel Hill. Dr. Ramsey is also the director of the UNC Center for Biomedical Microtechnologies, a center focused on fostering collaborations between medical researchers or clinicians and developers of microtechnologies for enhancing access to biological information. His present research interests include highly miniaturized mass spectrometry, micro- and nanofluidics, and single molecule DNA sequencing, single cell assays and point-of-care clinical diagnostic devices. Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), later renamed Caliper Life Sciences and acquired by PerkinElmer in late 2011 for $650M. Caliper is the leading commercial supplier of microfluidic technologies; tools primarily used in the pharmaceutical and biotechnology industries.
Individual/Angel
Christopher Obereder
United States
Mr. Armando Christian Perez was an Angel Investor. He was a Co-Founder of Armalite. He is an internationally successful musician, performer, business entrepreneur, fashion icon, and actor. His career sales have exceeded 5 million albums and 60 million singles worldwide. Pitbull has scored #1 hits in more than 15 countries, his videos have over 7 billion views, and his social media reach matches audiences of some television networks. After hosting the American Music Awards for the second time, Pitbull released his eighth studio album, Globalization on November 24. Pitbull partners with a number of guest artists on Globalization, including Jason Derulo, Juicy J, Heymous Molly and Sean Paul, as well as a new collaboration with Ne-Yo. Pitbull's world tours have sold out concerts in North and South America, Europe, and the Far East. He recently wrapped up the second leg of a co-headlining arena tour of the U.S. and Canada with Enrique Iglesias. 2014 was a banner year for Pitbull, who was chosen to perform at the opening ceremony of the FIFA World Cup in Sao Paolo, Brazil, and closed out the year with his New Year's Eve special. In addition to his success as a recording artist, Pitbull is also a burgeoning business entrepreneur. Along with Voli, his brand of premium vodka, he recently launched "Pitbull," his own line of luxury fragrances for men and women. In addition to inking major sponsorship deals with blue-chip brands like Bud Light, Dr. Pepper, Kodak, and Dodge, he is also developing a strategic partnership with Playboy Enterprises.
Individual/Angel
Chrysa Mineo
Greater San Diego Area, California, United States
Ms. Mineo has served as our Vice President, Corporate Development since July 2009 and is responsible for our collaborations with AbbVie, Ono...
Individual/Angel
Chuck Vallurupalli
United States
Mr. Michael Riccio is the Founder and served as Managing Partner at Falcon Partners. He also is an Angel Investor. Prior to founding the Firm, Mr. Riccio served as Chief Operating Officer of Go2Net, Inc. (Nasdaq: GNET) until its acquisition by Infospace, Inc. (Nasdaq: INSP) in a $1.7 billion stock transaction in October 2000. As COO and a member of Go2Net's Board of Directors, Mr. Riccio had overall responsibility for Go2Net's strategic initiatives, including business development, corporate development, mergers and acquisitions, strategic investments and international business strategy. Mr. Riccio also led Go2Net's corporate venture group which co-invested with Paul Allen's Vulcan Ventures in several Internet and e-commerce companies, including AskMe, Inc., Commtouch Software, Lts. (Nasdaq: CTCH), Click2Learn, Inc. (Nasdaq: CLKS), FindWhat, Inc. (Nasdaq: FWHT) and National Discount Brokers, Inc. (acquired by Deutsche Bank). After Go2Net's sale to Infospace, Mr. Riccio became Executive Vice President of Infospace, Inc. (Nasdaq: INSP), where he had overall responsibility for Infospace's Broadband Division focused on developing broadband services and applications for PC, TV and 2.5/3G wireless platforms. Mr. Riccio was instrumental in the development and launch of the first interactive TV service offered by Bloomberg Television in 2001 and the execution of a number of strategic alliances with such companies as Microsoft, Verizon, Liberate and OpenTV. Prior to joining Go2Net in 1998, Mr. Riccio was a corporate partner at Hutchins, Wheeler & Dittmar, a Boston based law firm where he specialized in mergers and acquisitions, private equity and corporate finance. Mr. Riccio served as principal outside counsel to Lycos, Inc. from the time of the company's founding in 1995. In this capacity, he worked closely with Lycos' senior management on its initial public offering and on many subsequent strategic transactions, including the formation of the joint venture with Bertelsmann AG and the acquisitions of Angelfire, Tripod, WhoWhere? and Wired Digital. Mr. Riccio also served as counsel to a number of private equity firms including CMG@Ventures, Highland Capital Partners, Summit Partners and Thomas H. Lee Equity Partners. As counsel, he participated in transactions with a number of Internet companies, including Blaxxun Interactive, eToys, Mapquest (acquired by AOL), NextCard, PlanetAll (acquired by Amazon.com), Quote.com (acquired by Lycos), RoweCom, Silknet Software (acquired by Kana Software) and Ticketslive (acquired by Tickets.com). Mr. Riccio served as a founding partner of Xanthus Capital, L.P., a Seattle based investment firm focused on investments in emerging growth businessess, and managing partner of Vencor & Co., a Boston based investment firm focused on investing in Internet and e-commerce enterprises. He also served as interim Chief Executive Officer of Hamlet, Inc., a developer of predictive pricing solutions for the travel industry funded by Madrona Investment Group and WRF Capital. Mr. Riccio began his career as an associate in the corporate department of Willkie, Farr & Gallagher in New York. Mr. Riccio currently serves as a member of the Board of Directors of Verdiem Corp., a developer of PC power management software, and Local Lead, LLC, a provider of online lead generation services for local merchants, and as a member of the Advisory Boards of Linqware, Inc., a developer of real time collaboration software, and Integra Ventures, L.P., a venture capital partnership focused on investing in biotechnology and life sciences enterprises.
Individual/Angel
Cisco Spark Innovation Fund
San Jose, California, United States
Cisco is a global leader in collaboration products and services
Computer
Professional Networking
Corporate Venture Capital
CITA|Emprende
San Sebastian, Pais Vasco, Spain
CITA|Emprende assembles SMEs, startups, and investors for possibilities of collaboration in the Open Innovation key.
Angel Investment
Financial Exchanges
Financial Services
Impact Investing
Venture Capital
Venture Capital
Clara Mobility
Japan
Bicycle Investment is a venture capital firm based in Tokyo, Japan. The firm invest in business areas surrounding bicycles and promote business collaboration and support utilizing the technology.
Venture Capital
Collaboration Capital
3131 Eastside St, Houston, TX 77098, United States
Investment service
Conectus
France
Operator of a first tech transfer acceleration company intended to provide access to all the public research in Alsace. The company provides an access point, manages risk, offers a portfolio of patents, sensitization and training, rights and commercialization and mapping and monitoring and facilitates research collaboration, contract and platform management and contract negotiations, enabling businesses to access technologies that are fully developed and ready to be integrated into an industrial development process.
Accelerator
Incubator
CONTENTshift
United States
Dr. Stephen Farr is a Co-Founder and serves as Board Member, President, and Chief Executive Officer at Zogenix. He serves as Chairman of Cerebral Therapeutics. He is a Board member of Flow Pharma. He has been actively involved in the private and public financing of Zogenix, raising in excess of $250 million, and leading the company through an IPO in November 2010. He is responsible for Research and Development, Clinical Development, Regulatory Affairs, and Quality and Manufacturing Development functions. In this role, he has overseen the development and NDA approval of Sumavel DosePro, a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, the Phase 2/3 development of Zohydro, an extended-release oral formulation of single-entity hydrocodone, and in developing the early-stage pipeline of products based upon the DosePro technology. From 1995 to August 2006, he held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. For 7 years, he led the inhaled insulin collaboration with Novo Nordisk and took the product from laboratory proof-of-concept to international Phase 3 clinical studies in Type 1 and Type 2 diabetes. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, he was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He has widely published on advanced drug delivery and was made a Fellow of the American Association of Pharmaceutical Scientists in 1998. He is an Adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University and also serves on the board of ICVRx, a start-up, a clinical-stage company focused on new treatments for the treatment of medically refractory epilepsy. He is a Member of the Royal Pharmaceutical Society (registered pharmacist in the United Kingdom) and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.
Individual/Angel
Showing 41 to
60 of
148 results